BMY acquires RYZB for $62.50/sh cash—a 104% premium to Friday’s close: https://www.globenewswire.com/news-release/2023/12/26/2801050/0/en/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio.html The nominal deal value is $3.6B. RYZB IPOd only three months ago at $18.00 (#msg-172827912). Hence, the investment return during this 3-month period was 247% (~3,600% annualized)!